NASDAQ · ACET
Adicet Bio, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for ACET: Nov 4, 2026
Adicet Bio, Inc. Common Stock is estimated to report earnings on 11/04/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 2 analysts' forecasts, the consensus EPS forecast for the quarter is $-1.56. The reported EPS for the same quarter last year was $-4.64.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-1.56 | $-1.07 | $-2.05 | 2 |
| Dec 2026 | $-1.59 | $-1.06 | $-2.12 | 2 |
| Mar 2027 | $-1.65 | $-1.10 | $-2.19 | 2 |
| Jun 2027 | $-1.54 | $-1.12 | $-1.95 | 2 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · The Motley Fool · Benzinga · Zacks- RTTNews · Sep 16, 3:58 AM EDTARPO To Report Glaucoma Trial Data In Q4, ARDX To Face FDA In April, PFE's Pipeline Update(RTTNews) – Today's Daily Dose brings you news about Aerpio Pharma's clinical trial catalyst, Adicet Bio's reverse merger with resTORbio, FDA decision date of Ardelyx's Tenapanor, Cel-Sci's phase III study of Multikine for the treatment of newly diagnosed head and neck cancer, a
- RTTNews · Dec 17, 6:34 AM ESTDrugs That Missed Key Goals In Phase III Trials(RTTNews) – The journey of a drug from the lab to medicine cabinet is long and uncertain.
- The Motley Fool · Nov 15, 11:35 AM ESTHere's Why resTORbio Fell Over 83% TodayWhat happened Shares of resTORbio (NASDAQ: TORC) fell over 83% today after the company reported that its lead drug candidate, RTB101, failed a late-stage clinical trial evaluating its potential to prevent respiratory illness in adults over 65. The company has discontinued develop
- RTTNews · Nov 15, 7:26 AM ESTResTORbio : Trial In Symptomatic Respiratory Illness Fails To Meet Primary Goal(RTTNews) – resTORbio, Inc., (TORC) said that data from the PROTECTOR 1 Phase 3 study, which evaluated the safety and efficacy of RTB101 in preventing clinically symptomatic respiratory illness in adults age 65 and older, did not meet its primary endpoint. It has stopped the deve
- Benzinga · Mar 19, 12:44 PM EDTMid-Day Market Update: StoneCo Jumps Following Strong Q4 Results; Aquabounty Technologies Shares SlideMidway through trading Tuesday, the Dow traded up 0.5 percent to 26,031.24 while the NASDAQ climbed 0.39 percent to 7,744.21. The S&P also rose,.
- Zacks · Jul 31, 9:53 AM EDTResTORbio (TORC) Continue to Surge Higher?As of late, it has definitely been a great time to be an investor in resTORbio, Inc. TORC . The stock has moved higher by 66.2% in the past month,.
- The Motley Fool · Jul 28, 8:38 AM EDT3 Healthcare Stocks That Skyrocketed 35% or More This Week: Are They Still Buys?If you could travel back in time just one week, it would be a smart move to buy a few stocks during your visit to the recent past. Three healthcare.
- The Motley Fool · Jul 25, 12:18 PM EDTWhy resTORbio, Inc. Stock Skyrocketed TodayWhat happened Shares of resTORbio, Inc. (NASDAQ: TORC) are skyrocketing today, up 65.5% as of 11:42 a.m. EDT, after the small biotech announced.
- NASDAQ.com News · Jul 25, 8:23 AM EDTPre-Market Most Active for Jul 25, 2018 : ERIC, FCAU, NXPI, F, TORC, GM, STM, KKR, XT, MU, QQQ, BAThe NASDAQ 100 Pre-Market Indicator is down -3.27 to 7,402.98. The total Pre-Market volume is currently 4,365,389 shares traded. The following.
- Renaissance Capital · May 1, 5:01 AM EDTCan Unity Biotechnology find a cure for age?One of the largest biotechs of the 2018 IPO market is going public this week. Unity Biotechnology ( UBX ) plans to raise $85 million at a market cap.
- DividendChannel.com · Apr 12, 10:57 AM EDTThursday 4/12 Insider Buying Report: ETM, TORCAs the saying goes, there are many possible reasons for an insider to sell a stock, but only one reason to buy — they expect to make money. So let's.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for Adicet Bio, Inc. from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.